Program
Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890
Its studies are mostly in Colorectal Neoplasms, led by Incyte.
Drug pageAnti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since Dec 9, 20253 company-led studies, 3 open or runningNext primary completion: Dec 29, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyte | 33 open or running | phase 3since Dec 9, 2025 | Apr 14, 2023 | Dec 29, 2028phase 3 · NCT07284849 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 14, 2023First study: phase 1 study in Solid TumorsFirst studyNCT05836324 · 570 planned · United States, China, Denmark and more
- Dec 9, 2025Phase 3 study in Colorectal NeoplasmsPhase 3 reachedNCT07284849 · 700 planned · United States, Argentina, Australia and more
- Sep 11, 2026Phase 2 study in Colorectal NeoplasmsNCT07823322 · 40 planned · United States, Puerto Rico
Ahead
- Dec 29, 2028Primary completion: phase 3 study in Colorectal NeoplasmsNCT07284849
- May 3, 2029Primary completion: phase 1 study in Solid TumorsNCT05836324
- May 14, 2029Primary completion: phase 2 study in Colorectal NeoplasmsNCT07823322
TargetBeta
“A bispecific antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279) and human transforming growth factor beta (TGF-beta) receptor II (TGFbRII), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07823322Colorectal Neoplasms · United States, Puerto Rico | 2 | Recruiting | May 14, 2029 | 40 |
| NCT07284849Colorectal Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Dec 29, 2028 | 700 |
| NCT05836324Solid Tumors · United States, China, Denmark and more | 1 | Recruiting | May 3, 2029 | 570 |
How it is read
Names in the registry
- “INCA33890”, 3 entries
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.